Phytera and Lilly to partner on infectious diseases:
This article was originally published in Clinica
Phytera and Eli Lilly are to collaborate in research to discover novel agents for the diagnosis and prevention of infectious fungal diseases. Phytera will receive an up-front equity investment, milestone payments and royalties. Lilly, based in Indianapolis, Indiana, will fund the project and have worldwide rights to commercialise any products. As part of the agreement, the Worcester, Massachusetts-based Phytera will provide its natural product chemistry for the bioassay-guided fractionation and Lilly will supply compounds for screening.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.